Zymeworks insider plans sale of 128,548 shares
Zymeworks Inc. insider plans to sell up to 128,548 shares of common stock through Morgan Stanley Smith Barney on or about 02/13/2026 on Nasdaq, with an aggregate market value of $2,978,457.16.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Zymeworks Inc. insider plans to sell up to 128,548 shares of common stock through Morgan Stanley Smith Barney on or about 02/13/2026 on Nasdaq, with an aggregate market value of $2,978,457.16. These shares relate mainly to an option exercise for 117,255 shares, vesting of 10,834 restricted stock units, and purchase of 459 shares under an employee stock purchase plan, all acquired in early 2026. Shares of common stock outstanding were 74,836,534 as of the time referenced, which serves as a baseline figure for the company’s capital structure.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.